The World Health Organisation (WHO) has begun a clinical trial in the Democratic Republic of the Congo (DR Congo) to test vaccine candidates against the Bundibugyo strain of Ebola. The research aims to improve protection against a virus that has no specifically approved vaccine.
The trial, known as Tumaini, began on Friday, October 23, in Bunia, the capital of Ituri province. Researchers will assess the safety and effectiveness of vaccine candidates and determine whether they can protect people against the strain.
The development comes as health authorities continue efforts to contain the Ebola outbreak in DR Congo. The trial could provide valuable evidence for future outbreak responses, although researchers must complete their assessments before drawing conclusions about the vaccines.
WHO Ebola Vaccine Trial in DR Congo Tests Candidates
The trial will initially evaluate Ervebo, a vaccine approved for Ebola disease caused by the Zaire strain. However, its effectiveness against the Bundibugyo strain remains uncertain.
Researchers will also assess additional candidates developed by Moderna and the University of Oxford in collaboration with the Serum Institute of India.
According to the WHO, the study will examine the vaccines’ safety and ability to trigger an immune response. Researchers will also investigate whether the candidates can prevent infection.
The trial will use a ring vaccination approach, which targets contacts of confirmed cases and other people at high risk of exposure. This strategy can help researchers evaluate vaccine performance while supporting efforts to limit the virus’s spread.
The WHO is supporting Congolese health authorities and research institutions in conducting the study.
Trial Could Strengthen Future Ebola Preparedness
The absence of an approved vaccine specifically targeting the Bundibugyo strain presents a major challenge for outbreak preparedness. Existing vaccines against other Ebola strains cannot automatically be assumed to provide protection against it.
The new trial could help scientists determine whether available or experimental candidates offer protection. Its findings may also guide the development of targeted vaccines for future outbreaks.
However, the start of the trial does not mean that an effective vaccine has already been established. Researchers must analyse the results before confirming the safety and effectiveness of any candidate against the strain.
Meanwhile, health authorities continue to rely on surveillance, contact tracing, infection prevention and public awareness to control the outbreak.
The trial marks an important step in Ebola research. Its results could help strengthen future responses to Bundibugyo outbreaks and improve preparedness for emerging public health threats.
